BR112013015898A2 - derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. - Google Patents
derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.Info
- Publication number
- BR112013015898A2 BR112013015898A2 BR112013015898-0A BR112013015898A BR112013015898A2 BR 112013015898 A2 BR112013015898 A2 BR 112013015898A2 BR 112013015898 A BR112013015898 A BR 112013015898A BR 112013015898 A2 BR112013015898 A2 BR 112013015898A2
- Authority
- BR
- Brazil
- Prior art keywords
- fatty acid
- acid derivative
- preparing
- methods
- water soluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426356P | 2010-12-22 | 2010-12-22 | |
| US61/426356 | 2010-12-22 | ||
| PCT/US2011/065591 WO2012087838A1 (en) | 2010-12-22 | 2011-12-16 | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013015898A2 true BR112013015898A2 (pt) | 2018-06-26 |
Family
ID=45464916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013015898-0A BR112013015898A2 (pt) | 2010-12-22 | 2011-12-16 | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8945897B2 (pt) |
| EP (2) | EP3673921A1 (pt) |
| JP (1) | JP6138052B2 (pt) |
| KR (1) | KR102025442B1 (pt) |
| CN (1) | CN103269723B (pt) |
| AR (1) | AR084576A1 (pt) |
| AU (2) | AU2011349574B9 (pt) |
| BR (1) | BR112013015898A2 (pt) |
| CA (1) | CA2822591C (pt) |
| DK (1) | DK2654794T3 (pt) |
| EA (1) | EA032056B1 (pt) |
| ES (1) | ES2800983T3 (pt) |
| HU (1) | HUE049352T2 (pt) |
| MX (1) | MX345608B (pt) |
| NZ (1) | NZ612320A (pt) |
| PL (1) | PL2654794T3 (pt) |
| PT (1) | PT2654794T (pt) |
| SG (1) | SG191298A1 (pt) |
| TW (1) | TWI546279B (pt) |
| WO (1) | WO2012087838A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015535304A (ja) * | 2012-09-10 | 2015-12-10 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 固相グリカンおよび糖ペプチド分析、ならびにグライコミクス抽出用マイクロ流体チップ、これを使用するための分析および方法 |
| CN103897031A (zh) * | 2012-12-25 | 2014-07-02 | 深圳先进技术研究院 | 化学修饰的胸腺五肽及其合成方法 |
| WO2014131011A1 (en) * | 2013-02-25 | 2014-08-28 | J Craig Venter Institute | Metaproteomic method to identify secreted pattern recognition molecules and adhesive antimicrobial factors for detection of microbial agents eliciting inflammation in the human host |
| CA2907378A1 (en) * | 2013-03-20 | 2014-09-25 | Fresenius Kabi Deutschland Gmbh | Process for the preparation of thiol functionalized hydroxyalkyl starch derivatives |
| CN103636918B (zh) * | 2013-12-13 | 2015-11-04 | 东北农业大学 | 一种富含亚油酸的改性分离蛋白制备方法 |
| WO2015095553A1 (en) * | 2013-12-20 | 2015-06-25 | Nephrogenesis, Llc | Methods and apparatus for kidney dialysis |
| EP2915569A1 (en) * | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| US10596232B2 (en) | 2015-08-12 | 2020-03-24 | Cell Machines, Inc. | Methods and compositions related to long half-life coagulation complexes |
| CN106554425B (zh) * | 2015-09-18 | 2018-10-30 | 沈阳药科大学 | 一种聚唾液酸的脂质接枝衍生物及其应用 |
| CN109069569B (zh) * | 2015-12-02 | 2023-02-14 | 韩美药品株式会社 | 使用脂肪酸衍生物的蛋白缀合物及其制备方法 |
| CN108147990B (zh) * | 2016-12-02 | 2023-01-24 | 上海中医药大学 | 一种膜锚定元件及其应用 |
| CN110637027A (zh) | 2017-02-08 | 2019-12-31 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
| CN107141354A (zh) * | 2017-05-05 | 2017-09-08 | 李斯文 | 一种融合蛋白及光敏剂复合物及其制备方法和应用 |
| WO2019023295A1 (en) | 2017-07-27 | 2019-01-31 | Saint Louis University | HUMAN EPIDERMAL GROWTH FACTOR MODIFIED BY FATTY ACID |
| AU2018336482B2 (en) * | 2017-09-19 | 2021-08-12 | Immunwork Inc. | Pharmaceutical constructs with enhanced binding affinity with albumin |
| CA3126476A1 (en) | 2019-01-23 | 2020-07-30 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| US11692020B2 (en) | 2019-11-20 | 2023-07-04 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
| US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| CN113967267B (zh) * | 2020-07-21 | 2022-10-25 | 四川大学 | 脂肪酸修饰的白蛋白的内质网靶向作用及其用途 |
| KR20230148819A (ko) | 2021-02-26 | 2023-10-25 | 리제너론 파마슈티칼스 인코포레이티드 | 글루코코르티코이드 및 안지오포이에틴-유사 7 (angptl7) 억제제를 이용한 염증의 치료 |
| EP4337680A1 (en) * | 2021-05-11 | 2024-03-20 | Cytoki Pharma ApS | Therapeutic derivatives of interleukin-22 |
| EP4089108A1 (en) * | 2021-05-11 | 2022-11-16 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| EP4089107A1 (en) * | 2021-05-11 | 2022-11-16 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CN114990175B (zh) * | 2021-10-22 | 2023-03-31 | 岩唐生物科技(杭州)有限责任公司 | 一种岩藻糖衍生物的合成方法 |
| WO2024026099A1 (en) * | 2022-07-29 | 2024-02-01 | The Trustees Of The University Of Pennsylvania | Lymphatic targeted anti-coagulant for the prevention of lymphatic thrombosis |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| US5153265A (en) | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| SE466754B (sv) | 1990-09-13 | 1992-03-30 | Berol Nobel Ab | Saett att kovalent binda biopolymerer till hydrofila ytor |
| EP0513332A4 (en) | 1990-11-14 | 1993-03-17 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
| JPH06506217A (ja) | 1991-03-18 | 1994-07-14 | エンゾン，インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
| DK0627924T3 (da) | 1992-10-02 | 2001-04-30 | Genetics Inst | Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| JP3014764B2 (ja) | 1993-09-17 | 2000-02-28 | ノボ ノルディスク アクティーゼルスカブ | アシル化インスリン |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
| AU6255096A (en) | 1995-06-07 | 1996-12-30 | Mount Sinai School Of Medicine Of The City University Of New York, The | Pegylated modified proteins |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| JP4187277B2 (ja) | 1997-04-30 | 2008-11-26 | エンゾン ファーマシューティカルズ， インコーポレイテッド | グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| CN1224712C (zh) | 1997-06-04 | 2005-10-26 | 牛津生物医学（英国）有限公司 | 载体 |
| US6531298B2 (en) | 1997-07-21 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Factor IX antihemophilic factor with increased clotting activity |
| WO2001082943A2 (en) | 2000-05-03 | 2001-11-08 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor vii |
| US6673575B1 (en) | 1997-12-03 | 2004-01-06 | Roche Diagnostics Gmbh | Method for preparing polypeptides with appropriate glycosilation |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US6596398B1 (en) | 1998-08-21 | 2003-07-22 | Atofina Chemicals, Inc. | Solar control coated glass |
| DK1400551T3 (da) | 1998-08-28 | 2007-10-15 | Amylin Pharmaceuticals Inc | Polyamidkæder med præcis længde og deres konjugater med proteiner |
| LT2599503T (lt) | 1998-10-16 | 2017-06-26 | Biogen Ma Inc. | Interferono beta-1a polimero konjugatai ir jų panaudojimas |
| DE19852729A1 (de) | 1998-11-16 | 2000-05-18 | Werner Reutter | Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung |
| DK2193809T3 (en) | 1999-02-22 | 2015-05-26 | Univ Connecticut | The albumin-free Factor VIII formulation |
| EP1183230A1 (en) * | 1999-06-08 | 2002-03-06 | La Jolla Pharmaceutical | Valency platform molecules comprising aminooxy groups |
| US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| YU32402A (sh) | 1999-11-12 | 2005-03-15 | Maxygen Holdings Ltd. | Konjugati gama interferona |
| US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| RU2278123C2 (ru) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
| AU2001254624A1 (en) | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Human coagulation factor vii variants |
| WO2001093914A2 (en) | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| JP4361728B2 (ja) | 2000-09-13 | 2009-11-11 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固因子ｖｉｉ変異型 |
| DE60137950D1 (de) | 2000-10-02 | 2009-04-23 | Novo Nordisk Healthcare Ag | Verfahren zur herstellung vitamin-k-abhängiger proteine |
| GB0103877D0 (en) * | 2001-02-16 | 2001-04-04 | King S College London | Novel Drug Delivery system |
| CA2441580A1 (en) | 2001-03-22 | 2002-10-03 | Novo Nordisk Health Care Ag | Coagulation factor vii derivatives |
| US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| ES2516041T3 (es) | 2001-10-10 | 2014-10-30 | Ratiopharm Gmbh | Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH) |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| CA2466027C (en) | 2001-11-07 | 2013-01-08 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| AU2002351197A1 (en) | 2001-11-28 | 2003-06-10 | Neose Technologies, Inc. | Glycopeptide remodeling using amidases |
| CA2468295C (en) | 2001-11-28 | 2010-08-03 | Neose Technologies, Inc. | Glycoprotein remodeling using endoglycanases |
| PT1517710E (pt) | 2002-06-21 | 2011-07-08 | Novo Nordisk Healthcare Ag | Glicoformas do factor vii peguilado |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| CA2496317C (en) | 2002-09-11 | 2014-02-18 | Fresenius Kabi Deutschland Gmbh | Method of producing hydroxyalkyl starch derivatives |
| EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
| DE02020425T1 (de) | 2002-09-11 | 2004-07-15 | Fresenius Kabi Deutschland Gmbh | Hasylierte Polypeptide, besonders hasyliertes Erythropoietin |
| US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| AU2003300139B2 (en) | 2002-12-31 | 2008-08-28 | Nektar Therapeutics | Maleamic acid polymer derivatives and their bioconjugates |
| WO2004060965A2 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| CN102139114A (zh) | 2003-02-26 | 2011-08-03 | 尼克塔治疗公司 | 聚合物-因子viii部分缀合物 |
| US7623892B2 (en) | 2003-04-02 | 2009-11-24 | Palm, Inc. | System and method for enabling a person to switch use of computing devices |
| WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
| TWI356065B (en) * | 2003-08-08 | 2012-01-11 | Fresenius Kabi De Gmbh | Method of producing hydroxyalkyl starch derivative |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| US20080206182A1 (en) | 2003-08-08 | 2008-08-28 | Fresenius Kabi Deutschland Gmbh | Conjugates of a Polymer and a Protein Linked by an Oxime Group |
| EP1654004A2 (en) | 2003-08-08 | 2006-05-10 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| ES2735809T3 (es) | 2003-08-12 | 2019-12-20 | Lipoxen Tech Limited | Derivativos del ácido siálico para la derivatización y conjugación de proteínas |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| WO2005055946A2 (en) | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
| JP4738346B2 (ja) | 2003-12-03 | 2011-08-03 | ノヴォ ノルディスク アー／エス | ＧｌｙｃｏＰＥＧ化された第ＩＸ因子 |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| JP5743368B2 (ja) | 2004-01-08 | 2015-07-01 | ラショファーム ゲーエムベーハー | ペプチドのｏ結合型グリコシル化 |
| WO2005092369A2 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyethyl starch and erythropoietin |
| GB0412181D0 (en) * | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| WO2006020372A2 (en) | 2004-07-23 | 2006-02-23 | Neose Technologies, Inc. | Enzymatic modification of glycopeptides |
| WO2006013202A2 (en) | 2004-08-02 | 2006-02-09 | Novo Nordisk Health Care Ag | Conjugation of fvii |
| US7875708B2 (en) | 2004-08-12 | 2011-01-25 | Lipoxen Technologies Limited | Sialic acid derivatives |
| EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| PL1824988T3 (pl) | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
| WO2006069246A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| EP1835938B1 (en) | 2004-12-27 | 2013-08-07 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
| EP1838332A1 (en) | 2005-01-06 | 2007-10-03 | Neose Technologies, Inc. | Glycoconjugation using saccharyl fragments |
| BRPI0607605A2 (pt) * | 2005-02-08 | 2009-09-15 | Queensland Inst Med Res | moléculas imunogênicas |
| JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー／エス | グリコペグ化第ｉｘ因子 |
| EP1896082B1 (en) | 2005-06-16 | 2012-12-26 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| US20090017007A1 (en) | 2005-08-26 | 2009-01-15 | Maxygen Holdings Ltd. | Liquid factor vii composition |
| KR20080038391A (ko) * | 2005-08-30 | 2008-05-06 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 페그화 성장 호르몬의 액체 제제 |
| CN101378782A (zh) | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| US20090093405A1 (en) * | 2006-01-19 | 2009-04-09 | Ambrx, Inc. | Non-Natural Amino Acid Polypeptides Having Modified Immunogenicity |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| WO2007140282A1 (en) | 2006-05-24 | 2007-12-06 | Peg Biosciences | Peg linker compounds and biologically active conjugates thereof |
| US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| US8097437B2 (en) | 2006-07-13 | 2012-01-17 | Serum Institute Of India Ltd. | Highly pure polysialic acid and process for preparation thereof |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| WO2008058547A2 (en) * | 2006-11-17 | 2008-05-22 | Nya Hamlet Pharma Ab | Alpha-lactalbumin composition |
| CN105838699A (zh) | 2006-12-15 | 2016-08-10 | 巴克斯艾尔塔公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
| MX2009007001A (es) | 2006-12-28 | 2009-07-10 | Ambrx Inc | Aminoacidos y polipeptidos fenazina y quinoxalina sustituidos. |
| JP5558106B2 (ja) | 2007-01-03 | 2014-07-23 | ノボ ノルディスク ヘルス ケア アーゲー | 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与 |
| WO2008119815A1 (en) | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
| DK2173383T3 (en) | 2007-06-26 | 2017-09-25 | Baxalta GmbH | HYDROLYSIBLE POLYMERIC FMOC LINKER |
| AU2008272792B2 (en) | 2007-07-03 | 2014-03-06 | Children's Hospital & Research Center At Oakland | Oligosialic acid derivatives, methods of manufacture, and immunological uses |
| CN101820920B (zh) | 2007-10-09 | 2014-08-06 | 宝力泰锐克斯有限公司 | 新的缀合蛋白质和肽 |
| EP2070951A1 (en) | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Method for producing a hydroxyalkyl starch derivatives with two linkers |
| EP2242505A4 (en) | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| MY158228A (en) | 2008-04-24 | 2016-09-15 | Cantab Biopharmaceuticals Patents Ltd | Factor ix conjugates with extended half-lives |
| JP2011520999A (ja) | 2008-05-23 | 2011-07-21 | ノボ ノルディスク ヘルス ケア アーゲー | 高濃度の芳香族保存料を有するペグ官能化セリンプロテアーゼの製剤 |
| EP2285401A1 (en) | 2008-05-23 | 2011-02-23 | Novo Nordisk Health Care AG | Low viscosity compositions comprising a pegylated gla-domain containing protein |
| EP2297330A4 (en) | 2008-06-04 | 2012-03-14 | Bayer Healthcare Llc | FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| CA2740793A1 (en) | 2008-11-03 | 2010-06-03 | Haiyan Jiang | Method for the treatment of hemophilia |
| US20120121613A1 (en) | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
| CN102333788A (zh) | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
| EP2403538B1 (en) | 2009-03-04 | 2017-10-04 | Polytherics Limited | Conjugated proteins and peptides |
| US20100330033A1 (en) | 2009-04-16 | 2010-12-30 | Nian Wu | Protein-carrier conjugates |
| US20120134977A1 (en) | 2009-06-01 | 2012-05-31 | Yeda Research And Development Co. Ltd. | Prodrugs containing albumin binding probe |
| EP2461821A4 (en) | 2009-07-31 | 2013-07-03 | Bayer Healthcare Llc | MODIFIED POLYPEPTIDES OF FACTOR IX AND USES THEREOF |
| DE102009028526A1 (de) | 2009-08-13 | 2011-02-24 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Verfahren zur Modifikation und Funktionalisierung von Sacchariden |
| WO2011037896A2 (en) | 2009-09-25 | 2011-03-31 | Vybion, Inc. | Polypeptide modification |
| WO2011064247A1 (en) | 2009-11-24 | 2011-06-03 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
| JP5914363B2 (ja) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー／エス | 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子 |
| CN102812039B (zh) * | 2010-02-16 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | 缀合蛋白质 |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| HUE043790T2 (hu) | 2010-07-30 | 2019-09-30 | Baxalta GmbH | Nukleofil katalizátorok oximkötésekhez |
| US20130331554A1 (en) | 2010-11-15 | 2013-12-12 | Biogen Idec Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
| ES2722209T3 (es) | 2011-07-08 | 2019-08-08 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos e híbridos del Factor VIII, y métodos de uso de los mismos |
-
2011
- 2011-12-16 SG SG2013048194A patent/SG191298A1/en unknown
- 2011-12-16 PL PL11806103T patent/PL2654794T3/pl unknown
- 2011-12-16 EA EA201390940A patent/EA032056B1/ru unknown
- 2011-12-16 PT PT118061035T patent/PT2654794T/pt unknown
- 2011-12-16 EP EP19211476.7A patent/EP3673921A1/en not_active Withdrawn
- 2011-12-16 WO PCT/US2011/065591 patent/WO2012087838A1/en active Application Filing
- 2011-12-16 MX MX2013007369A patent/MX345608B/es active IP Right Grant
- 2011-12-16 NZ NZ612320A patent/NZ612320A/en unknown
- 2011-12-16 ES ES11806103T patent/ES2800983T3/es active Active
- 2011-12-16 CA CA2822591A patent/CA2822591C/en active Active
- 2011-12-16 KR KR1020137019066A patent/KR102025442B1/ko active IP Right Grant
- 2011-12-16 US US13/329,002 patent/US8945897B2/en active Active
- 2011-12-16 AU AU2011349574A patent/AU2011349574B9/en active Active
- 2011-12-16 HU HUE11806103A patent/HUE049352T2/hu unknown
- 2011-12-16 DK DK11806103.5T patent/DK2654794T3/da active
- 2011-12-16 BR BR112013015898-0A patent/BR112013015898A2/pt not_active Application Discontinuation
- 2011-12-16 CN CN201180062472.4A patent/CN103269723B/zh active Active
- 2011-12-16 JP JP2013546263A patent/JP6138052B2/ja active Active
- 2011-12-16 EP EP11806103.5A patent/EP2654794B8/en active Active
- 2011-12-21 TW TW100147675A patent/TWI546279B/zh active
- 2011-12-22 AR ARP110104911A patent/AR084576A1/es active IP Right Grant
-
2017
- 2017-06-14 AU AU2017204019A patent/AU2017204019A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011349574B2 (en) | 2017-06-01 |
| CN103269723A (zh) | 2013-08-28 |
| SG191298A1 (en) | 2013-07-31 |
| US20120190096A1 (en) | 2012-07-26 |
| ES2800983T3 (es) | 2021-01-07 |
| WO2012087838A1 (en) | 2012-06-28 |
| HUE049352T2 (hu) | 2020-09-28 |
| US8945897B2 (en) | 2015-02-03 |
| EA032056B1 (ru) | 2019-04-30 |
| TWI546279B (zh) | 2016-08-21 |
| MX2013007369A (es) | 2013-09-26 |
| KR20130129254A (ko) | 2013-11-27 |
| TW201305090A (zh) | 2013-02-01 |
| JP6138052B2 (ja) | 2017-05-31 |
| MX345608B (es) | 2017-02-07 |
| EP3673921A1 (en) | 2020-07-01 |
| KR102025442B1 (ko) | 2019-09-25 |
| AU2011349574A1 (en) | 2013-07-11 |
| JP2014501262A (ja) | 2014-01-20 |
| EA201390940A1 (ru) | 2014-04-30 |
| CN103269723B (zh) | 2017-04-05 |
| AU2011349574B9 (en) | 2017-06-15 |
| PL2654794T3 (pl) | 2020-07-27 |
| NZ612320A (en) | 2015-06-26 |
| EP2654794A1 (en) | 2013-10-30 |
| CA2822591C (en) | 2020-12-29 |
| EP2654794B1 (en) | 2020-03-04 |
| AR084576A1 (es) | 2013-05-29 |
| DK2654794T3 (da) | 2020-06-08 |
| CA2822591A1 (en) | 2012-06-28 |
| AU2017204019A1 (en) | 2017-07-06 |
| PT2654794T (pt) | 2020-06-11 |
| EP2654794B8 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013015898A2 (pt) | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. | |
| BRPI1011486A2 (pt) | Método para obter preparações de proteína a partir de sementes de girassol, preparação de proteína, uso da preparação, e, produto. | |
| BR112013015221A2 (pt) | cápsula, sistema e método para o preparo de uma bebida | |
| DK2539015T3 (da) | Nethindeprotese | |
| BR112014010186A2 (pt) | formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal | |
| BRPI1011764A2 (pt) | composição farmacêutica, e, método para preparar uma composição farmacêutica | |
| BR112012025470A2 (pt) | sistema para reconstruir informações cardíacas, montagem para facilitar a reconstruçã de informações cardíacas, e método para reconstrução de informações cardíacas | |
| BRPI1010950A2 (pt) | método para preparação de emulsão carregada de fármaco. | |
| BR112013002765A2 (pt) | implante deflectível, sistema e métodos para implantação do mesmo | |
| BR112013021368A2 (pt) | implante, especialmente para oclusão de abeurismas bifurcais | |
| ITMI20111404A1 (it) | Supporto per articolazioni umane. | |
| BRPI1014035A2 (pt) | método para contracepção. | |
| BRPI0922173A2 (pt) | preparação farmacêutica, e, método para preparar uma preparação farmacêutica | |
| BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
| IL222566A0 (en) | Conjugated blood coagulation factor viii | |
| BR112013014103A2 (pt) | método para produzir um l-aminoácido | |
| BR112014013694A2 (pt) | método para tratar uma doença, e, kit | |
| BR112014009789A2 (pt) | cisteamina no tratamento da doença fibrótica | |
| BR112012004300A2 (pt) | preparação de ácido acético. | |
| PT2539352T (pt) | Composições e métodos para tratar doenças cardíacas | |
| CO7020857A2 (es) | Procedimiento para la preparación de complejos de 68ga | |
| IL233238A0 (en) | Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use | |
| EP2533763C0 (de) | Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide | |
| BR112013014737A2 (pt) | hidrolisados de proteína vegetal | |
| BR112013013415A2 (pt) | composição farmacêutica, e, método para a preparação de uma composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: BAXALTA GMBH (CH) ; BAXALTA INCORPORATED (US) |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 47/48 , A61P 7/00 Ipc: A61K 47/54 (2017.01), A61K 47/60 (2017.01), A61K 3 |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |